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Does desmopressin improve hemostasis and 
reduce blood loss from aortic surgery? A 
randomized, double-blind study 
G. Patrick Clagett, MD, R. James Valentine, MD, Stuart I. Myers, MD, 
Anm Chervu, MD, and JoAnn Heller, RN, BSN, Dallas, Texas 
Purpose: The purpose of this study was to determine the effect of desmopressin acetate 
(DDAVP) on blood loss, transfusion requirements, and thromboembolic complications in 
patients undergoing elective aortic operations. 
Methods: A randomized, ouble-blind trial was carried out during a 3-year period with 
patients receiving 20 wg DDAVP or identical-appearing placebo at the time of aortic 
cross-clamp lacement. In addition to major bleeding and thromboembolic end points, 
bleeding times and platelet counts were monitored serially. 
Results: Forty-three patients were randomized to receive DDAVP, and 48 were assigned 
to a placebo. An equivalent proportion of patients with aneurysm and patients with 
occlusive disease was in each group. In spite of mild prolongation i  the postoperative 
bleeding times and moderate thrombocytopenia, DDAVP had no beneficial effect on blood 
loss or transfusion requirements. Total blood transfusion amotmt (mean -+ standard 
deviation) for patients receiving DDAVP was 3.1 + 3.0 U compared with 2.7 +- 3.0 U for 
those receiving placebo. For all patients the period associated with the greatest blood loss 
was the time between heparin administration with cross-clamp application and reversal of 
heparin with protamine sulfate. The incidence of major thromboembolic complications 
was similar in both groups. 
Conclusion: Thrombocytopenia and mild platelet dysfunction are common after aortic 
operation, but DDAVP does not improve hemostasis or lessen transfusion requirements. 
This study does not rule out a beneficial effect of DDAVP in patients who are undergoing 
more complex aortic operations or who have major hemostatic aberrations. (J VAse SuRa 
1995;22:223-30.) 
Desmopressin acetate, 1-deamino-8-D-arginine 
vasopressin (DDAVP), is a synthetic vasopressin 
analog that lacks vasoconstrictor activity and acutely 
increases levels of Factor VIII and von Willebrand 
factor (vWF) when administered intravenously. 1 It 
has been used to improve hemostasis n patients with 
mild hemophilia and von Willebrand's disease; it 
shortens the bleeding time in these patients appar- 
ently by inducing endothelial release of large multi- 
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meric forms ofvWF. 2-3 The increase in titer o fvWF 
is paralleled by increased platelet adhesiveness to 
vessel wall denuded of endothelium and is most likely 
the mechanism responsible for improvement of 
hemostasis. 4 DDAVP has also been shown to shorten 
the bleeding time and reduce surgical blood loss and 
blood transfusion requirements in other conditions 
associated with platelet dysfunction and bleeding 
such as uremia, s'6 aspirin ingestion, 7 heparin admin- 
istration, s certain congenital and acquired platelet 
disorders, 9q2 and cardiopulmonary bypass. 13 A1- 
though there appears to be no significant reduction in 
blood loss and transfusion with uncomplicated car- 
diopulmonary bypass and short pump runs ,  14-19 
prophylactic use o fDDAVP appears to benefit hose 
having complex cardiac operations. 2°Postoperative 
treatment is helpful in improving hemostasis in 
patients with ongoing hemorrhage and severe plate- 
let dysfunction after cardiopulmonary bypass is 
performed. 21
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DDAVP has also been evaluated in patients 
undergoing major orthopedic surgical procedures 
who have normal hemostasis and no known defects 
of platelet function. Although the results in patients 
having total joint (hip or knee) arthroplasty are 
corlflicting, 22,23 a single, randomized, double-blind 
trial in patients undergoing spinal fusion operation 
demonstrated significant reductions inblood loss and 
transfusion in patients receiving DDAVP. 24 These 
findings have led to the recommendation t  consider 
prophylactic DDAVP for operations associated wirk 
major blood loss 25,26 and have formed the principal 
rationale to test the efficacy of prophylactic DDAVP 
in patients undergoing an aortic surgical procedure. 
The hypotheses addressed were that (1) DDAVP 
would reduce blood loss and transfusion i  patients 
tmdergoing aortic operation, and (2) DDAVP would 
not lead to thromboembolic complications in pa- 
tients with disseminated vascular disease. 
METHODS 
Patients undergoing elective infrarenal aortic 
aneurysm repair or aortofemoral bypass for occlusive 
disease were eligible for entrance into this study. 
Patients with the following conditions were 
ineligible: aspirin ingestion within 7 days of opera- 
tion, acquired or congenital hemorrhagic diathesis, 
emergency operation, creatinine _> 3 mg~dl, thoraco- 
abdominal reconstruction, aortorenal or visceral by- 
pass, or refusal to join the smdy. Informed consent 
was obtained from each patient before ntry into the 
study, and the protocol was approved by the Human 
Studies Committee of the Dallas Veterans Adminis- 
tration Medical Center. Randomization was carried 
out in blocks of 10 and was stratified for repalr of 
abdominal aortic anenrysm or aortofemoral bypass 
for occlusive disease. Patients were randomized by 
drawing a sealed envelope that containcd a prescrip- 
tion for either 20 txg DDAVI' (Rorer Pharmaceuti- 
cals, Fort Washington, Pa.) or placebo. The only 
person to have knowledge of treatment assignment 
was the pharmacist who kept records and prepared 
DDAVP or placebo in identical-appearing plastic 
bags of 50 ml normal saline solution. DDAVP or 
placebo was administered intravenously for 15 min- 
utes immediately after intravenous heparinization 
with 100 U/kg was performed and just before aortic 
cross-clamp application was done. Forty-five minutes 
after initial heparin administration, a supplemental 
intravenous dose of 50 U/kg was given to some 
patients. At the end of the operation reversal of 
heparin was carried out by giving protamine stflfate 
in a dose of 0.75 to 1.0 mg for every 100 U ofheparin 
administered. Activated clotting times were not 
routinely monitored. Autotransfusion a d cell-saver 
devices were specifically proscribed in these patients. 
Major end-points for analysis included blood loss, 
blood transfusion requirements, and arterial and 
venous thromboembolic complications. Blood loss 
was monitored uring operation according to stan- 
dard techniques that included sponge weights, mea- 
surement of amounts collected in drainage canisters 
(total minus field irrigation with normal saline 
solutions), and nurses' and anesthesiologists' e ti- 
mates. In most cases a research nurse was present in 
the operating room to monitor blood loss. The 
operative blood loss was assessed at three time 
periods: (1) from skin incision to heparinization a d 
application of aortic crossclamps, (2) the period 
during which aortic and vascular cross-clamps were 
in place and the patients were given a fvll course of 
heparin and (3) the period from reversal of heparin 
with protamine sulfate to completion of operation. 
Blood transfusion requirements were monitored 
during operation and for 72 hours in the postoper- 
ative period. In addition, colloid, electrolyte solu- 
tions, and blood component therapy (fresh-frozen 
plasma nd platelet concentrate) were also recorded 
during these intervals. 
Bleeding times were performed 1 day before 
operation, the day of operation immediately after the 
procedure was performed, and 1 day after operation. 
Bleeding times were assessed with a disposable 
template device (Simplate, General Diagnostic) ac- 
cording to the Ivy method as modified by MieNe et 
al. 27 In addition, routine hematologic parameters 
that included platelet cotmt, hematocrit, hemoglo- 
bin, and electrolytes were monitored at these inter- 
vals and throughout the postoperative p riod while 
patients were in the intensive care unit. 
Statistical analysis was by Student's t test for 
nonparametric data, and all data presented in tables 
and text are mean + standard eviation. Propor- 
tional data were assessed with the chi-squared test. 
Analysis ofvariance (one-way) was used to assess the 
effect of time period on blood loss, transfusion, and 
other parameters. 
RESULTS 
During a 4-year period 91 patients were recruited 
into this study, and this group represented approxi- 
mately 45% of patients undergoing aortic surgical 
procedures at the Dallas VA Medical Center during 
that time period. Reasons for being excluded in- 
cluded urgent or emergency operation, anticipated 
complex aortic operation (concomitant renal or 
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Table I. Patient characteristics 
DDA VP (n = 43) Placebo (n = 48) 
Age 62 ± 9 64 ± 8 
Male (%) 43 (100) 48 (100) 
Aortic aneurysm (%) 25 (58) 27 (56) 
Occlusive disease (%) 18 (42) 21 (44) 
Aneurysm size (cm) 6.4 ± 1.3 6.3 ± 1.5 
Weight (kg) 77 +- 18 82 ± 17 
Height (cm) 177 ± 6 180 ± 7 
Smoke (%) 43 (100) 46 (96) 
Pack-years 41 -+ 12 39 ± 13 
Hypertension (%) 23 (54) 25 (52) 
Hypercholesterolemia (%) 5 (11) 5 (10) 
Diabetes (%) 7 (16) 9 (19) 
Coronary artery disease (%) 19 (44) 25 (52) 
Chronic obstructive pulmonaß disease (%) I6 (32) 19 (40) 
Creatinine _>2 mg/dl (%) 5 (12) 8 (19) 
visceral artery bypass, thoracoabdominal repair), 
recent aspirin ingestion, other hemorrhagic diathesis, 
patient refiasal, or nonavailability ofresearch person- 
nel. Forty-three patients were randomized to receive 
DDAVP, and 48 were assigned to a placebo. Patient 
demographics and risk factors are shown in Table I. 
All patients were male, and no significant differences 
were seen between groups in age, body habitus, 
smoking history, hypertension, diabetes mellitus, 
chronic obstructive pulmonary disease, elevated cho- 
lesterol, coronary artery disease, and renal insuffi- 
ciency (creatinine between 1.8 and 3.0 mg/dl). 
Slightly more than one half the patients in each group 
underwent operation for aortic aneurysm, and no 
significant difference was seen between groups in 
aneurysm size (Table I). 
Operative information and transfusion require- 
ments are in Table II. Total operative time and aortic 
cross-clamp time were similar between DDAVP and 
placebo groups. Although the total dose of heparin 
administered to both groups was equivalent, signifi- 
cantly more protamine sulfate was given to patients 
who received DDAVP. On further analysis this 
difference was due to patients randomized toplacebo 
who underwent operation for aneurysm and were 
given less protamine sulfate. There was no plausible 
reason for' this difference, and it remains unexplained. 
No significant differences were seen between 
groups in total estimated blood loss or in blood loss 
during three operative periods (Table II). More 
important, no difference was seen in the amount of 
blood transfusion given during the operation or in 
the 3 days after operation. The total amount (opera- 
tive and postoperative) of blood transfusion for 
patients receiving DDAVP was 3.1 +-3.0 U of 
packed red cells and 2.7-+ 3.0 U from those 
receiving placebo. Twenty-seven percent of patients 
receiving placebo did not require blood transfusion 
compared with 23% of those randomized to receive 
DDAVP. These differences were not significant. The 
lack of benefit of DDAVP was apparent in both 
patients with aneurysm and patients with occlusive 
disease. There were also no diffcrences in crystalloid 
or colloid administration or the use of blood com- 
ponent herapy (data not shown). 
Because there was no apparent effect of DDAVP 
on estimated blood loss or transfusion requirements, 
patients with aneurysm and occlusive disease were 
analyzed separately regardless oftheir group random- 
ization. These data are in Table III. The total 
estimated blood loss for patients undergoing opera- 
tion for aortic aneurysm was significantly greater than 
for those having aortofemoral bypass for occlusive 
disease. This difference was mostly due to blood loss 
during the period of aortic cross-clamp when esti- 
mated loss from patients undergoing operation for 
aneurysm was nearly twice that of those having 
aortofemoral bypass. For all patients (aneurysm and 
occlusive disease) the period from application of 
aortic cross-clamps to reversal of heparin with 
protamine sulfate was associated with the greatest 
blood loss. For all patients the interaction between 
time period and blood loss was highly significant 
(F = 25.0, p < 0.0001). It was surprising that in 
spite of the differences inestimated blood loss among 
patients with aneurysm and occlusive disease, the 
operative, postoperative, and total transfusion re- 
quirements were only slightly and not significantly 
increased inpatients undergoing operation for aortic 
aneurysm. 
Bleeding times immediately after operation and 1 
day later were modestly but significantly prolonged 
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Table II. Blood loss, transfusion requirements, and other operative details 
DDAVP (n = 43) Placebo (n = 48) 
Operative details 
Operative time (min) 235 + 73 252 _+ 76 
Cross-clamp time 83 + 43 82 -+ 30 
Heparin ( x 103u) 14.8 _+ 4.9 13.6 + 7.6 
Protamine (mg) 146 -+ 50 122 _+ 43* 
Estimated blood loss (tal) 
Before cross-damp 248 + 235 200 _+ 170 
Cross-clamp 858 _+ 997 823 _+ 5ö5 
After cross-clamp 406 -+ 605 296 +_ 415 
Total estimated blood loss 1470 + 1200 1332 _+ 843 
RBC Transfusion (U) 
Intraoperative 1.9 _+ 2.2 1.7 _+ 1.8 
Postoperative 1.2 _+ 1.6 1.0 _+ 2.0 
Total 3.1 -+ 3.0 2.7 _+ 3.0 
No transfusion (%) 10 (23) 13 (27) 
*p < 0.03. 
Table III. Estimated blood loss (ml) during operation among patients with aortic aneurysm and 
occlusive disease 
Beföre cross-clamp During cross-clamp After cross-damp Total blood loss 
Aneurysm (n = 52) 246 _+ 228 1034 _+ 927* 283 _+ 287 1621 -+ 1163" 
Occlusive disease (n = 39) 188 _+ 181 1623 -+ 544 443 _+ 718 1080 -+ 902 
All patients (n = 91) 224 _+ 204 841 + 808~- 356 _+ 519 1379 _+ 1082 
*p < 0.025 compared with blood loss during same time period in patients with occlusive disease. 
~F = 25.0, p < 0.0001 for blood loss during cross-clamp in all patients. 
in comparison with preoperative values in all pa- 
tients, and no differences were seen between groups 
(Fig. 1, Table IV). Conversely, platelet counts 
decreased in the postoperative period by approxi- 
mately 30% in both groups (Fig. 2, Table IV). 
Hematocrits also decreased to the same degree in 
both groups, and no differences were noted through- 
out the postoperative period (Table IV). Because 
DDAVP may influence water excretion and electro- 
lyte concentration, postoperative sodium, potassium, 
and creatinine l vels were assessed and noted to be 
not significantly different among groups (data not 
shown). 
Thrombotic omplications were assessed by ma- 
jor clinical outcomes. Among patients receiving 
DDAVP, two patients had postoperative (within 30 
days) myocardial infarction, one had deep venous 
thrombosis and pulmonary embolism, and three had 
acute limb ischemia requiring thrombectomy. The 
overall incidence in major postoperative thrombotic 
episodes among patients receiving DDAVP was 
14%. This rate was similar (15%) to that of patients 
receiving placebo in whom there were four episodes 
of myocardial infarction, a single case of bowel 
infarction, and two instances of acute lower limb 
ischemia. Three patients in each group required 
subsequent infrainguinal bypass for unrelieved or 
worsening lower extremity ischemia. Two deaths 
occurred in this series (overall mortality = 2.2%), 
and both occurred in patients receiving DDAVP 
(one had pulmonary embolus, and one had myocar- 
dial infarction). 
DISCUSSION 
This study did not find a beneficial effect of 
DDAVP in patients undergoing elective aortic op- 
erations. DDAVP had no apparent effect on hemo- 
stasis and did not lessen blood transfusion require- 
ments. This negative result was present both in 
patients with aortic aneurysms and in those with 
occlusive disease. DDAVP appears to be most 
effective in surgical situations in which severe platelet 
dysfunction is present, as in complex heart operations 
with prolonged pump r t lns ,  13'2°'21 or  where there are 
large wounds with continuous microvascular bleed- 
ing that might be expected to respond m improved 
platelet-dependent, primary hemostasis. 24 
Mild platelet dysfunction as indicated by a slight 
prolongation of the bleeding time and moderate 
thrombocytopenia regularly occurred in patients 
having aortic operations. These hemostatic abnor- 
malities were part of the rationale m test DDAVP in 
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Table IV. Serial laboratory values 
Immediately aJ~er 
Preoperative operation Postoperative day1 Postoperative day 2 Postoperative day 3 
Bleeding time (sec) 
DDAVP 307 -+ 103 408 + 231" 377 _+ 162 
Placebo 313 _+ 95 395 + 175" 397 -+ 152 
Platelet count ( × 103/txl) 
DDAVP 309 -- 88 215 + 66# 196 -+ 54 
Placebo 269 + 8ö 191 -+ 66# 176 + 58 
Hematocrit (%) 
DDAVP 39.7 + 4.6 32.6 -+ 3.9 31.3 - 3.3 
Placebo 40.6 + 5.1 34.2 + 4.6 33.3 + 3.9 
w 
162 + 52 166 +-- 49 
151 + 43 157 + 39 
29.5 -+ 3.4 30.1 +- 3.2 
31.3 + 3.9 30.5 _+ 3.2 
*p < 0.025 compared to preoperative alues 
#p < 0.001 compared to preoperative alues 
this setting. Thrombocytopenia is most likely due to 
consumption of platelets in the surgical wound and 
on the aortic prosthesis. The reason for mild platelet 
dysfunction is less clear. Animal studies have docu- 
mented reversible interaction of platelets with aortic 
prostheses, and this process eems to lead to mild 
degrees of in vivo platelet release resulting in a 
platelet biLochemical profile resembling that of ac- 
quired storage pool deficiency. 28These abnormalities 
have been confirmed in patients with Dacron vascular 
prostheses. 29 Whatever the mechanism underlying 
the mild prolongation of the bleeding time is, it is 
unlikcly to be clinically important or to lead to major 
blood loss, becanse all bleeding times, although 
prolonged, remained within normal imits. 
An interesting finding in this study was that the 
greätest arnount of operative blood loss occurred 
between heparinization with application of cross- 
clamps and rcvcrsal of heparin with protamine 
sulfate. Heparin administration regularly prolongs 
the bleeding tlme, 3° and this effect is partially 
corrected by the administration of DDAVP. 8 The 
adverse ffect of heparin is thought o be due to its 
binding with vWF, which interferes with vWF's 
binding to platelets, 31 a receptor-mediated vent 
necessary for platelet adhesion to subendothelial 
surfaces. Because the effect of heparin is due to 
competiuve inhibition, increasing levels of vWF by 
administering DDAV-P would be expected to im- 
prove platelet-dependent hemostasis. It was disap- 
pointing that DDAVP did not lessen blood loss 
during heparinization i patients undergoing aortic 
operations. 
Most of the blood loss during aortic surgical 
procedures stems from necessary technical maneuvers 
that involve large vessel bleeding. These technical 
problems leading to so-called "mechanical b eeding" 
include retrograde bleeding from lumbar and other 
branches after the aorta is opened, bleeding during 
placement of arteriotomies, bleeding during "flush- 
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ing" of anastomoses, bleeding from gaps in anasto- 
motic suture lines, and bleeding through interstices 
of porous prostheses. Control of bleeding from these 
sources depends on skiU and technical means and not 
on improving physiologic hemostasis. 
This smdy does not rule out a beneficial effect of 
DDAVP in patients undergoing aortic surgical 
procedures who have preexisting hemostatic aberra- 
tions such as recent aspirin ingestion or in those who 
have diffuse microvascular bleeding as a postopera- 
tive complication. In fact, the absence of adverse 
events in this study gives reassurance that DDAVP 
will not cause major thrombotic omplications in 
patients with diffuse vascular disease who are treated 
because of bleeding complications. 
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DISCUSSION 
Dr. Stanley O. Snyder (Norfolk, Va.). I want to 
congratulate Dr. Clagett and his colleagues on this 
excellent presentation of an important randomized 
double-blind study. Your äbility to enforce aspirin avoid- 
ance and enroll 50% of the VA hospital aortic surgery 
population in this study was impressive, and the 2.2 
percent mortality rate in this group is admirable. 
The use of DDAVP has been widely debated in the 
cardiac literature but has not been previously weU studied 
in patients with peripheral vascular disease. Your conclu- 
sions of n,o beneficial effect on blood loss or transfusion 
requirements are consistent with at least seven randomized 
cardiac series in which DDAVP was not beneficial for 
routine coronary artery bypass grafting. ~3 However, there 
äre other raudomized cardiac series in which either more 
complex procedures were performed or significant platelet 
dysfunction or aspirin ingestion preceded surgery, in which 
perioperative blood loss was decreased, postoperative 
bleeding times were corrected, and in one series 2~ postop- 
erative bleeding was actively treated by DDAVP regimens. 
I have three questions. In your study DDAVP was 
given after heparin administration and before aortic 
cross-clamping. In all the cardiac series DDAVP was given 
after cessation of cardiopulmonary b pass and after full 
reversal of heparin with protamine. Because heparin 
functions by competitive inhibition in binding von Will- 
ebrand factor to prevent its binding to platelets and 
subsequent adhesion to subendothelial surfaces, could 
more benefit be noted only ifone waited until after heparin 
reversal before using DDAVP? 
What is your poststudy protocol for DDAVP in your 
practice? Do you use it for patients with postoperative 
bleeding problems? Do you recommend it prophylactically 
for complex procedures such as thoracoabdominal aortic 
aneurysm repair or in patients with metabofic or 
medication-induced platelet dysfunction? 
You noted no electrolyte problems, but because 
DDAVP was initially developed as an antidiuretic for the 
treatment of diabetes insipidus, was there any difference 
noted in the postoperative weight gain or subsequent 
timing of third space mobilization in the DDAVP group? 
Dr. G. Patrick Clagett. In response to the first 
question, the kinetics of von Willebrand factor elease from 
endothelium under the influence of desmopressin is such 
that it really should last beyond the period of aortic 
cross-clamping, so there should be some effect beyond that 
period. 
In addition, we demonstrated that most of the blood 
loss occurred uring the period of aortic cross-clamp and 
heparin administration. Heparin definitely prolongs the 
bleeding time, and as you point out this is due to 
competitive inhibition with von Willebrand factor, which 
may be reversed by the administration of DDAVP. It 
therefore made sense to us that this would be the period 
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when the benefit would be realized by DDAVP. Unfortu- 
nately we did not see a benefit, because there are mechanical 
sources of bleeding that simply overwhelm any beneficial 
hemostatic effect hat one might see with this agent. 
What is our current practice? We use it occasionally in
a patient who has ingested aspirin, a uremic patient, or a 
patient with cirrhosis in whom you have to do major aortic 
procedure. I think it can be helpful in improving hemostasis 
in these patients, and we use it under those conditions. We 
do not recommend it for thoracoabdominal aneurysm 
repair. If we did not see any benefit in routine infrarenal 
aortic aneurysm repair, I am sure we would not see any 
benefit under those circumstances. We do use it in those 
special cases that I mentioned, and the fact that we did not 
see thrombotic omplications gives me some reassurance 
that it can be used in patients with platelet dysfunction 
from drugs or other causes who are undergoing aortic 
surgical procedures. 
As rar as the weight gain after operation, it was highly 
variable, orten inaccurate, and we did not really see any 
overt differences or any clinically apparent differences in 
terms of third space mobilization. 
And, yes, we do routinely use autotransfusion for aortic 
aneurysm operation. We did not use cell-saver devices in 
this study, because we believed that introducing another 
variable having impact on transfusion requirements might 
obscure differences between groups. 
Dr. Lazar Greenfield (Ann Arbor, Mich.). I do not 
have rauch experience with the drug, but it occurs to me 
that you have three drugs interacting, and I am curious 
about customary pharmacology where you have to have a 
dose-response curve. How do you know you have the 
correct dosage, and was there any measurement of specific 
values that you could measure to ensure that the correct 
dosage is being applied? 
Dr. Clagett. We used the dosage recommendation that 
comes from the cardiac surgery literature and also the other 
trials that have been done on patients undergoing major 
orthopaedic surgery. To measure the effect of DDAVP, 
one can use an indirect measure such as the bleeding time. 
We did this and did not see an effect. As a matter of fact 
most of the studies that have looked at this have not seen 
an effect on shortening the bleeding time under these 
circumstances, eren in the patients undergoing cardiac 
surgical procedures who, interestingly, have a reduction in 
transfusion requirements. One can also measure von 
Willebrand factor; we did not do that. 
Dr. Alan Lumsden (Atlanta, Ga.). I think you are to 
be congratulated. Within the confines of your smdy I 
certainly would accept he conclusion, but you have a very 
rigorously controlled experimental group: no aspirin and 
no cell saver. I would take a little bit of issue with your 
conclusions in terms oflumping together thrombocytope- 
nia and platelet dysfunction. Those are really two very 
different issues. You clearly ger consumption ofplatelets or 
reduction in platelets around the period of the aortic 
surgical procedure. It is very difficult to sott out whether 
that is due to an absolute reduction in number of platelets 
or relative dilution, which occurs with all the fluid shifts. 
We have looked at platelet counts, and they certainly go 
down, and the platelet markers, platelet factor IV, and 13 
thromboglobulin go up, suggesting platelet consumption, 
but it is difficult to know whether you are truly getting an 
absolute reduction in platelet count. 
The second point is that the platelet dysfunction is 
really a very important issue because you may not have had 
dysfunctional p atelets. You may have had reduced num- 
bers of normally functioning platelets, and that is not the 
group of patients who would benefit from this procedure, 
so although within the confines ofyour study I think your 
conclusions are absolutely correct- it may be that there are 
groups of patients uch as those receiving aspirin, such as 
those with borderline renal failure, who may benefit from 
desmopressin, and I would ask whether you have any 
preliminary data in which you häve specifically looked at 
those patients who are known to have dysfunctional 
platelets. 
Dr. Clagett. First of all, with regard to the consump- 
tion of platelets, that has been well documented. Platelet 
survival studies in patients undergoing aortic procedures 
show marked consumption of platelets. There is an 
absolute decrease in platelet count because of platelet 
interactions with the prosthetic surface and also the healing 
wound. 
Whether there is dysfunction or consumption of 
normal platelets leaving behind dysfunctional p atelets or 
whether there is an actual biomaterial-induced platelet 
dysfunction, we cannot really say. The experimental 
literature would suggest hat there is reversible platelet 
interaction with the prosthetic surface that leads to release 
of platelet granular contents as reflected by increases in 13 
thromboglobulin a d decreases in platelet granule constitu- 
ents. This may be likened to a mild platelet storage pool 
deficiency state, and that has been pretty weil documented. 
Eren these theoretic issues aside, there are sorne studies that 
have looked at the use of desmopressin patients with 
normal platelets and no dysfunction, and they häve 
demonstrated a bene~cial effect in terms of bleeding and 
blood transfusion requirements. That was an additional 
stimulus to study the effect of desmopressin patients 
undergoing aortic procedures. Platelet dysfunction is 
extremely mild, if it is present at all, and it is not clinically 
significant. 
